RxDoctor Payments Data

Lindsay Dunlop

Psychiatric/Mental Health · Cortland, NYNPI 1437760311

Payments from drug & device makers

$545in general payments, 2019–2025

Across 19 payments — averaging $28.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$202
  • Alkermes, Inc.$145
  • Neurocrine Biosciences, Inc.$117
  • Teva Pharmaceuticals USA, Inc.$33
  • E.r. Squibb & Sons, L.L.C.$19
  • AbbVie$16
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$53798%
  • Education$82%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$545 in reported general payments places this provider in the 55th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York

Medicare billing

Part B allowed, 2024
$68,257
Medicare patients
90
Services billed
798

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide81$67,902
EliquisApixaban82$23,453
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$15,602
EntrestoSacubitril/Valsartan31$10,929
FarxigaDapagliflozin Propanediol30$8,977
XareltoRivaroxaban23$6,114
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog21$4,761
Fluticasone-SalmeterolFluticasone Propion/Salmeterol32$4,263
Aripiprazole14$3,564
Incruse ElliptaUmeclidinium Bromide30$3,351
Divalproex Sodium71$3,299
MyrbetriqMirabegron13$2,990
FenofibrateFenofibrate Nanocrystallized39$2,389
Atorvastatin Calcium151$1,787
Bumetanide31$1,664

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$14$67,90281 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in Cortland

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →